US pharmaceutical company Upsher-Smith Laboratories LLC, a subsidiary of Taiwan-based Bora Pharmaceuticals Co Ltd (TW:6472) (OTCQX:BORAY) announced on Monday the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP.

The product is a generic version of Bayer AG's Ciprodex, a prescription medicine used to treat ear infections.

According to IQVIA, the market for Ciprofloxacin and Dexamethasone Otic Suspension had US sales of approximately USD118m.

"The introduction of Upsher-Smith's first prescription ear drop suspension reinforces our strategic focus on expanding and diversifying our generics portfolio to support sustainable, long-term growth," said Jim Maahs, senior vice president, head of Upsher-Smith Commercial. "By adding Ciprofloxacin and Dexamethasone Otic Suspension, we continue to strengthen our presence in differentiated dosage forms while delivering options that meet the needs of our customers and the patients they serve."

The Therapeutic Equivalence (TE) code for Upsher-Smith's Ciprofloxacin and Dexamethasone Otic Suspension product is AB, and the Reference Listed Drug (RLD) is the brand Ciprodex.